@article{Adeyinka2022,
  title = {{{COVID-19 Vaccination}} and {{Public Health Countermeasures}} on {{Variants}} of {{Concern}} in {{Canada}}: {{Evidence From}} a {{Spatial Hierarchical Cluster Analysis}}},
  shorttitle = {{{COVID-19 Vaccination}} and {{Public Health Countermeasures}} on {{Variants}} of {{Concern}} in {{Canada}}},
  author = {Adeyinka, Daniel A. and Neudorf, Cory and Camillo, Cheryl A. and Marks, Wendie N. and Muhajarine, Nazeem},
  year = {2022},
  month = may,
  journal = {JMIR Public Health and Surveillance},
  volume = {8},
  number = {5},
  pages = {e31968},
  publisher = {{JMIR Publications Inc., Toronto, Canada}},
  doi = {10.2196/31968},
  urldate = {2023-11-14},
  abstract = {Background: There is mounting evidence that the third wave of COVID-19 incidence is declining, yet variants of concern (VOCs) continue to present public health challenges in Canada. The emergence of VOCs has sparked debate on how to effectively control their impacts on the Canadian population. Objective: Provincial and territorial governments have implemented a wide range of policy measures to protect residents against community transmission of COVID-19, but research examining the specific impact of policy countermeasures on the VOCs in Canada is needed. Our study objective was to identify provinces with disproportionate prevalence of VOCs relative to COVID-19 mitigation efforts in provinces and territories in Canada. Methods: We analyzed publicly available provincial- and territorial-level data on the prevalence of VOCs in relation to mitigating factors, summarized in 3 measures: (1) strength of public health countermeasures (stringency index), (2) the extent to which people moved about outside their homes (mobility index), and (3) the proportion of the provincial or territorial population that was fully vaccinated (vaccine uptake). Using spatial agglomerative hierarchical cluster analysis (unsupervised machine learning), provinces and territories were grouped into clusters by stringency index, mobility index, and full vaccine uptake. The Kruskal-Wallis test was used to compare the prevalence of VOCs (Alpha, or B.1.1.7; Beta, or B.1.351; Gamma, or P.1; and Delta, or B.1.617.2 variants) across the clusters. Results: We identified 3 clusters of vaccine uptake and countermeasures. Cluster 1 consisted of the 3 Canadian territories and was characterized by a higher degree of vaccine deployment and fewer countermeasures. Cluster 2 (located in Central Canada and the Atlantic region) was typified by lower levels of vaccine deployment and moderate countermeasures. The third cluster, which consisted of provinces in the Pacific region, Central Canada, and the Prairies, exhibited moderate vaccine deployment but stronger countermeasures. The overall and variant-specific prevalences were significantly different across the clusters. Conclusions: This ``up to the point'' analysis found that implementation of COVID-19 public health measures, including the mass vaccination of populations, is key to controlling VOC prevalence rates in Canada. As of June 15, 2021, the third wave of COVID-19 in Canada is declining, and those provinces and territories that had implemented more comprehensive public health measures showed lower VOC prevalence. Public health authorities and governments need to continue to communicate the importance of sociobehavioural preventive measures, even as populations in Canada continue to receive their primary and booster doses of vaccines.},
  copyright = {Unless stated otherwise, all articles are open-access distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work ("first published in the Journal of Medical Internet Research...") is properly cited with original URL and bibliographic citation information. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.},
  langid = {english},
  file = {C:\Users\jchen\Zotero\storage\UYCXUHVQ\Adeyinka et al. - 2022 - COVID-19 Vaccination and Public Health Countermeas.pdf}
}

@article{Brinc2021,
  title = {Evaluation of {{Dried Blood Spot Testing}} for {{SARS-CoV-2 Serology Using}} a {{Quantitative Commercial Assay}}},
  author = {Brinc, Davor and Biondi, Mia J. and Li, Daniel and Sun, Heng and Capraru, Camelia and Smookler, David and Zahoor, Muhammad Atif and Casey, Julia and Kulasingam, Vathany and Feld, Jordan J.},
  year = {2021},
  month = jun,
  journal = {Viruses},
  volume = {13},
  number = {6},
  pages = {962},
  publisher = {{Multidisciplinary Digital Publishing Institute}},
  issn = {1999-4915},
  doi = {10.3390/v13060962},
  urldate = {2024-02-21},
  abstract = {Dried blood spots (DBS) are commonly used for serologic testing for viruses and provide an alternative collection method when phlebotomy and/or conventional laboratory testing are not readily available. DBS collection could be used to facilitate widespread testing for SARS-CoV-2 antibodies to document past infection, vaccination, and potentially immunity. We investigated the characteristics of Roche's Anti-SARS-CoV-2 (S) assay, a quantitative commercial assay for antibodies against the spike glycoprotein. Antibody levels were reduced relative to plasma following elution from DBS. Quantitative results from DBS samples were highly correlated with values from plasma (r2 = 0.98), allowing for extrapolation using DBS results to accurately estimate plasma antibody levels. High concordance between plasma and fingerpick DBS was observed in PCR-confirmed COVID-19 patients tested 90 days or more after the diagnosis (45/46 matched; 1/46 mismatched plasma vs. DBS). The assessment of antibody responses to SARS-CoV-2 using DBS may be feasible using a quantitative anti-S assay, although false negatives may rarely occur in those with very low antibody levels.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  keywords = {antibody,COVID-19,dried blood spot,SARS-CoV-2,serology},
  file = {C:\Users\jchen\Zotero\storage\XCGBLTCD\Brinc et al. - 2021 - Evaluation of Dried Blood Spot Testing for SARS-Co.pdf}
}

@article{cameron2021variation,
  title = {Variation in the {{Canadian}} Provincial and Territorial Responses to {{COVID-19}}},
  author = {{Cameron-Blake}, Emily and Breton, Charles and Sim, Paisley and Tatlow, Helen and Hale, Thomas and Wood, Andrew and Smith, Jonathan and Sawatsky, Julia and Parsons, Zachary and Tyson, Katherine},
  year = {2021}
}

@techreport{CLSA2023,
  title = {{{COVID-19 Antibody Study Findings}} {\textbar} {{Canadian Longitudinal Study}} on {{Aging}}},
  author = {CLSA},
  year = {2023},
  institution = {{Canadian Longitudinal Study on Aging}},
  urldate = {2023-11-17},
  file = {C:\Users\jchen\Zotero\storage\S64SBNAQ\antibody-study-results.html}
}

@article{Drakeley2005,
  title = {Estimating Medium- and Long-Term Trends in Malaria Transmission by Using Serological Markers of Malaria Exposure},
  author = {Drakeley, C. J. and Corran, P. H. and Coleman, P. G. and Tongren, J. E. and McDonald, S. L. R. and Carneiro, I. and Malima, R. and Lusingu, J. and Manjurano, A. and Nkya, W. M. M. and Lemnge, M. M. and Cox, J. and Reyburn, H. and Riley, E. M.},
  year = {2005},
  month = apr,
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  volume = {102},
  number = {14},
  pages = {5108--5113},
  issn = {0027-8424},
  doi = {10.1073/pnas.0408725102},
  abstract = {The implementation and evaluation of malaria control programs would be greatly facilitated by new tools for the rapid assessment of malaria transmission intensity. Because acquisition and maintenance of antimalarial antibodies depend on exposure to malaria infection, such antibodies might be used as proxy measures of transmission intensity. We have compared the prevalence of IgG antibodies with three Plasmodium falciparum asexual stage antigens in individuals of all ages living at varying altitudes encompassing a range of transmission intensities from hyper- to hypoendemic in northeastern Tanzania, with alternative measures of transmission intensity. The prevalence of antibodies to merozoite surface protein-1(19) was significantly more closely correlated with altitude than either point-prevalence malaria parasitemia or single measures of hemoglobin concentration. Analysis of age-specific seroprevalence rates enabled differentiation of recent (seasonal) changes in transmission intensity from longer-term transmission trends and, using a mathematical model of the annual rate of seroconversion, estimation of the longevity of the antibody response. Thus, serological tools allow us to detect variations in malaria transmission over time. Such tools will be invaluable for monitoring trends in malaria endemicity and the effectiveness of malaria control programs.},
  langid = {english},
  pmcid = {PMC555970},
  pmid = {15792998},
  keywords = {Adult,Altitude,Animals,Antibodies Protozoan,Antigens Protozoan,Child,Child Preschool,Cross-Sectional Studies,Humans,Immunoglobulin G,Infant,Malaria Falciparum,Membrane Proteins,Merozoite Surface Protein 1,Middle Aged,Plasmodium falciparum,Protein Subunits,Protozoan Proteins,Seroepidemiologic Studies,Tanzania},
  file = {C:\Users\jchen\Zotero\storage\LXQ4YJ4M\Drakeley et al. - 2005 - Estimating medium- and long-term trends in malaria.pdf}
}

@article{Hale2021,
  title = {A Global Panel Database of Pandemic Policies ({{Oxford COVID-19 Government Response Tracker}})},
  author = {Hale, Thomas and Angrist, Noam and Goldszmidt, Rafael and Kira, Beatriz and Petherick, Anna and Phillips, Toby and Webster, Samuel and {Cameron-Blake}, Emily and Hallas, Laura and Majumdar, Saptarshi and Tatlow, Helen},
  year = {2021},
  month = mar,
  journal = {Nature Human Behaviour},
  volume = {5},
  number = {4},
  pages = {529--538},
  issn = {2397-3374},
  doi = {10.1038/s41562-021-01079-8},
  urldate = {2023-11-14},
  abstract = {Canadian provinces and territories took highly divergent approaches to the COVID-19 pandemic. Using the Oxford COVID-19 Government Response Tracker indicators and aggregate stringency indices, this paper explores variation in the timing and relative stringency of government responses across 13 Canadian provinces and territories. Canada is a decentralized federation where provinces and territories develop policies to fit local epidemiological and political contexts. The authors find that many smaller, less populous provinces and territories created the conditions for greater freedom of movement and `normalcy' as compared to larger provinces. With the creation of regional zones and tiered policy triggers, most regions have adopted reactive policies and restrictions, often too late, and not without unintended confusion. To date, the authors find that the benefits of federalism have been unevenly leveraged, a lack of coordination in planning and communication between the provinces and territories is an area of opportunity for improved future pandemic planning.},
  langid = {english},
  file = {C:\Users\jchen\Zotero\storage\L79NZFRG\Hale et al. - 2021 - A global panel database of pandemic policies (Oxfo.pdf}
}

@article{Karp2020,
  title = {A Serological Assay to Detect {{SARS-CoV-2}} Antibodies in at-Home Collected Finger-Prick Dried Blood Spots},
  author = {Karp, Donna Grace and Danh, Kenneth and Espinoza, Noemi Fonseca and Seftel, David and Robinson, Peter V. and Tsai, Cheng-ting},
  year = {2020},
  month = nov,
  journal = {Scientific Reports},
  volume = {10},
  pages = {20188},
  issn = {2045-2322},
  doi = {10.1038/s41598-020-76913-6},
  urldate = {2023-11-30},
  abstract = {Accurate surveillance of coronavirus disease 2019 (COVID-19) incidence requires large-scale testing of the population. Current testing methods require in-person collection of biospecimens by a healthcare worker, limiting access of individuals who do not have access to testing facilities while placing both patients and healthcare workers at risk of exposure to infection. We report the development and validation of a at-home finger-prick dried blood spot collection kit and an analysis method. We demonstrated 100\% sensitivity and specificity using at-home collected specimens across the US. Such methods may facilitate the conduct of unbiased serosurveys within hard to reach populations and help reduce the sample collection burden of serological testing on both health care systems and individuals alike.},
  pmcid = {PMC7678827},
  pmid = {33214612},
  file = {C:\Users\jchen\Zotero\storage\GVDV7UW2\Karp et al. - 2020 - A serological assay to detect SARS-CoV-2 antibodie.pdf}
}

@article{Larios2011,
  title = {Self-{{Collected Mid-Turbinate Swabs}} for the {{Detection}} of {{Respiratory Viruses}} in {{Adults}} with {{Acute Respiratory Illnesses}}},
  author = {Larios, Oscar E. and Coleman, Brenda L. and Drews, Steven J. and Mazzulli, Tony and Borgundvaag, Bjug and Green, Karen and Study, STOP-Flu and McGeer, Allison J.},
  year = {2011},
  month = jun,
  journal = {PLOS ONE},
  volume = {6},
  number = {6},
  pages = {e21335},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0021335},
  urldate = {2023-11-27},
  abstract = {Background The gold standard for respiratory virus testing is a nasopharyngeal (NP) swab, which is collected by a healthcare worker. Midturbinate (MT) swabs are an alternative due to their ease of collection and possible self-collection by patients. The objective of this study was to compare the respiratory virus isolation of flocked MT swabs compared to flocked NP swabs. Methods Beginning in October 2008, healthy adults aged 18 to 69 years were recruited into a cohort and followed up for symptoms of influenza. They were asked to have NP and MT swabs taken as soon as possible after the onset of a fever or two or more respiratory symptoms with an acute onset. The swabs were tested for viral respiratory infections using Seeplex{\textregistered} RV12 multiplex PCR detection kit. Seventy six pairs of simultaneous NP and MT swabs were collected from 38 symptomatic subjects. Twenty nine (38\%) of these pairs were positive by either NP or MT swabs or both. Sixty nine (91\%) of the pair results were concordant. Two samples (3\%) for hCV OC43/HKU1 and 1 sample (1\%) for rhinovirus A/B were positive by NP but negative by MT. One sample each for hCV 229E/NL63, hCV OC43/HKU1, respiratory syncytial virus A, and influenza B were positive by MT but negative by NP. Conclusions Flocked MT swabs are sensitive for the diagnosis of multiple respiratory viruses. Given the ease of MT collection and similar results between the two swabs, it is likely that MT swabs should be the preferred method of respiratory cell collection for outpatient studies. In light of this data, larger studies should be performed to ensure that this still holds true and data should also be collected on the patient preference of collection methods.},
  langid = {english},
  keywords = {Fevers,Influenza,Influenza B virus,Patients,Respiratory infections,Respiratory syncytial virus,Rhinovirus infection,Virus testing},
  file = {C:\Users\jchen\Zotero\storage\LBIR7BEC\Larios et al. - 2011 - Self-Collected Mid-Turbinate Swabs for the Detecti.pdf}
}

@article{Mackett2022a,
  title = {Do Instructions for At-Home Dried Blood Spot ({{DBS}}) Collection Affect the Quality of Collection? {{Data}} from the {{Canadian Longitudinal Study}} on {{Aging}} ({{CLSA}}) {{COVID-19}} Seroprevalence Study},
  shorttitle = {Do Instructions for At-Home Dried Blood Spot ({{DBS}}) Collection Affect the Quality of Collection?},
  author = {Mackett, K. and Oz, U. E. and Naik, C. and Vandenberghe, H. and Ivica, J. and Lawson, L. and Kyorkis, S. and Balion, C.},
  year = {2022},
  journal = {Clinical Biochemistry},
  pages = {115--115},
  urldate = {2023-11-09},
  langid = {english},
  file = {C:\Users\jchen\Zotero\storage\9RX735HA\covidwho-2242975.html}
}

@article{McDade2020,
  title = {High Seroprevalence for {{SARS-CoV-2}} among Household Members of Essential Workers Detected Using a Dried Blood Spot Assay},
  author = {McDade, Thomas W. and McNally, Elizabeth M. and Zelikovich, Aaron S. and D'Aquila, Richard and Mustanski, Brian and Miller, Aaron and Vaught, Lauren A. and Reiser, Nina L. and Bogdanovic, Elena and Fallon, Katherine S. and Demonbreun, Alexis R.},
  year = {2020},
  journal = {PloS One},
  volume = {15},
  number = {8},
  pages = {e0237833},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0237833},
  abstract = {OBJECTIVE: Serological testing is needed to investigate the extent of transmission of SARS-CoV-2 from front-line essential workers to their household members. However, the requirement for serum/plasma limits serological testing to clinical settings where it is feasible to collect and process venous blood. To address this problem we developed a serological test for SARS-CoV-2 IgG antibodies that requires only a single drop of finger stick capillary whole blood, collected in the home and dried on filter paper (dried blood spot, DBS). We describe assay performance and demonstrate its utility for remote sampling with results from a community-based study. METHODS: An ELISA to the receptor binding domain of the SARS-CoV-2 spike protein was optimized to quantify IgG antibodies in DBS. Samples were self-collected from a community sample of 232 participants enriched with health care workers, including 30 known COVID-19 cases and their household members. RESULTS: Among 30 individuals sharing a household with a virus-confirmed case of COVID-19, 80\% were seropositive. Of 202 community individuals without prior confirmed acute COVID-19 diagnoses, 36\% were seropositive. Of documented convalescent COVID-19 cases from the community, 29 of 30 (97\%) were seropositive for IgG antibodies to the receptor binding domain. CONCLUSION: DBS ELISA provides a minimally-invasive alternative to venous blood collection. Early analysis suggests a high rate of transmission among household members. High rates of seroconversion were also noted following recovery from infection. Serological testing for SARS-CoV-2 IgG antibodies in DBS samples can facilitate seroprevalence assessment in community settings to address epidemiological questions, monitor duration of antibody responses, and assess if antibodies against the spike protein correlate with protection from reinfection.},
  langid = {english},
  pmcid = {PMC7428174},
  pmid = {32797108},
  keywords = {Adolescent,Adult,Aged,Antibodies Viral,Betacoronavirus,Coronavirus Infections,COVID-19,Dried Blood Spot Testing,Enzyme-Linked Immunosorbent Assay,Family Characteristics,Female,Health Personnel,Humans,Immunoglobulin G,Male,Middle Aged,Pandemics,Pneumonia Viral,SARS-CoV-2,Seroepidemiologic Studies,Serologic Tests,Spike Glycoprotein Coronavirus,Young Adult},
  file = {C:\Users\jchen\Zotero\storage\TX2XA597\McDade et al. - 2020 - High seroprevalence for SARS-CoV-2 among household.pdf}
}

@article{Meyers2021,
  title = {Comparison of {{Dried Blood Spots}} and {{Venous Blood}} for the {{Detection}} of {{SARS-CoV-2 Antibodies}} in a {{Population}} of {{Nursing Home Residents}}},
  author = {Meyers, Eline and Heytens, Stefan and Formukong, Asangwing and Vercruysse, Hanne and De Sutter, An and Geens, Tom and Hofkens, Kenneth and Janssens, Heidi and Nys, Eveline and Padalko, Elizaveta and Deschepper, Ellen and Cools, Piet},
  year = {2021},
  month = sep,
  journal = {Microbiology Spectrum},
  volume = {9},
  number = {2},
  pages = {e00178-21},
  issn = {2165-0497},
  doi = {10.1128/Spectrum.00178-21},
  urldate = {2023-10-30},
  abstract = {In the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, testing for SARS-CoV-2-specific antibodies is paramount for monitoring immune responses in postauthorization vaccination and seroepidemiological studies. However, large-scale and iterative serological testing by venipuncture in older persons can be challenging. Capillary blood sampling using a finger prick and collection on protein saver cards, i.e., dried blood spots (DBSs), has already proven to be a promising alternative. However, elderly persons have reduced cutaneous microvasculature, which may affect DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS tests for the detection of SARS-CoV-2 antibodies among nursing homes residents. We collected paired venous blood and DBS samples on two types of protein saver cards (Whatman and EUROIMMUN) from nursing home residents, as well as from staff members as a reference population. Venous blood samples were analyzed for the presence of SARS-CoV-2 IgG antibodies using the Abbott chemiluminescent microparticle immunoassay (CMIA). DBS samples were analyzed by the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 IgG antibodies. We performed a statistical assessment to optimize the ELISA cutoff value for the DBS testing using Youden's J index. A total of 273 paired DBS-serum samples were analyzed, of which 129 were positive, as assessed by the reference test. The sensitivities and specificities of DBS testing ranged from 95.0\% to 97.1\% and from 97.1\% to 98.8\%, respectively, depending on the population (residents or staff members) and the DBS card type. Therefore, we found that DBS sampling is a valid alternative to venipuncture for the detection of SARS-CoV-2 antibodies among elderly subjects., IMPORTANCE Since the implementation of newly developed SARS-CoV-2 vaccines in the general population, serological tests are of increasing importance. Because DBS samples can be obtained with a finger prick and can be shipped and stored at room temperature, they are optimal for use in large-scale SARS-CoV-2 serosurveillance or postauthorization vaccination studies, even in an elderly study population.},
  pmcid = {PMC8557917},
  pmid = {34549995},
  file = {C:\Users\jchen\Zotero\storage\6CQ6AMHD\Meyers et al. - Comparison of Dried Blood Spots and Venous Blood f.pdf}
}

@article{Morley2020,
  title = {Sensitive {{Detection}} of {{SARS-CoV-2-Specific Antibodies}} in {{Dried Blood Spot Samples}}},
  author = {Morley, Gabriella L. and Taylor, Stephen and Jossi, Sian and {Perez-Toledo}, Marisol and Faustini, Sian E. and {Marcial-Juarez}, Edith and Shields, Adrian M. and Goodall, Margaret and Allen, Joel D. and Watanabe, Yasunori and Newby, Maddy L. and Crispin, Max and Drayson, Mark T. and Cunningham, Adam F. and Richter, Alex G. and O'Shea, Matthew K.},
  year = {2020},
  month = dec,
  journal = {Emerging Infectious Diseases},
  volume = {26},
  number = {12},
  pages = {2970--2973},
  issn = {1080-6059},
  doi = {10.3201/eid2612.203309},
  abstract = {Dried blood spot (DBS) samples can be used for the detection of severe acute respiratory syndrome coronavirus 2 spike antibodies. DBS sampling is comparable to matched serum samples with a relative 98.1\% sensitivity and 100\% specificity. Thus, DBS sampling offers an alternative for population-wide serologic testing in the coronavirus pandemic.},
  langid = {english},
  pmcid = {PMC7706975},
  pmid = {32969788},
  keywords = {Antibodies Viral,antibody,Case-Control Studies,coronavirus disease,COVID-19,COVID-19 Serological Testing,DBS,dried blood spot,Dried Blood Spot Testing,Humans,Predictive Value of Tests,respiratory infections,SARS-CoV-2,severe acute respiratory syndrome coronavirus 2,Spike Glycoprotein Coronavirus,viruses,zoonoses},
  file = {C:\Users\jchen\Zotero\storage\4C6HXKXZ\Morley et al. - 2020 - Sensitive Detection of SARS-CoV-2-Specific Antibod.pdf}
}

@article{Mulchandani2021,
  title = {Use of Dried Blood Spot Samples for {{SARS-CoV-2}} Antibody Detection Using the {{Roche Elecsys}} {\textregistered} High Throughput Immunoassay},
  author = {Mulchandani, Ranya and Brown, Ben and Brooks, Tim and Semper, Amanda and Machin, Nicholas and Linley, Ezra and Borrow, Ray and Wyllie, David and {Taylor-Philips}, Sian and Jones, Hayley and Oliver, Isabel and Charlett, Andre and Hickman, Matthew and Brooks, Tim and Mulchandani, Ranya and Wyllie, David},
  year = {2021},
  month = mar,
  journal = {Journal of Clinical Virology},
  volume = {136},
  pages = {104739},
  issn = {1386-6532},
  doi = {10.1016/j.jcv.2021.104739},
  urldate = {2024-02-21},
  abstract = {Dried blood spot samples (DBS) provide an alternative sample type to venous blood samples for antibody testing. DBS are used by NHS for diagnosing Hepatitis C and by Public Health England for large scale HIV and Hepatitis C serosurveillance; the applicability of DBS based approaches for SARS-CoV-2 antibody detection is uncertain. The study aimed to compare antibody detection in DBS eluates using the Roche Elecsys {\textregistered} immunoassay with antibody detection in paired plasma samples, using the same assay. The study was in one Police and one Fire \& Rescue facility in England; it comprised of 195 participants within a larger sample COVID-19 serodiagnostics study of keyworkers, EDSAB-HOME. Outcome measures were sensitivity and specificity of DBS (the index test) relative to plasma (the reference test), at an experimental cut-off; quality of DBS sample collected; estimates of relative sensitivity of DBS vs. plasma immunoassay in a larger population. 18/195 (9.2\%) participants tested positive using plasma samples. DBS sample quality varied markedly by phlebotomist, and low sample volume significantly reduced immunoassay signals. Using an experimental cut-off, sensitivity and specificity of DBS were 89.0\% (95\% CI 67.2, 96.9\%) and 100.0\% (95\% CI 97.9, 100\%) respectively compared with using plasma. The limit of detection for DBS is about 30 times higher than for plasma. DBS use for SARS-CoV-2 serology, though feasible, is insensitive relative to immunoassays on plasma. Sample quality impacts on assay performance. Alternatives, including the collection of capillary blood samples, should be considered for screening programs.},
  keywords = {antibody,COVID-19,Dried Blood Spots,SARS-CoV-2,serology},
  file = {C\:\\Users\\jchen\\Zotero\\storage\\P88PJETT\\Mulchandani et al. - 2021 - Use of dried blood spot samples for SARS-CoV-2 ant.pdf;C\:\\Users\\jchen\\Zotero\\storage\\D268RBNV\\S1386653221000068.html}
}

@article{Nakai2023,
  title = {Variation in Antibody Titers Determined by {{Abbott}} and {{Roche Elecsys SARS-CoV-2}} Assays in Vaccinated Healthcare Workers},
  author = {Nakai, Miku and Yokoyama, Daisuke and Sato, Tomoaki and Sato, Ryohei and Kojima, Chiari and Shimosawa, Tatsuo},
  year = {2023},
  month = jun,
  journal = {Heliyon},
  volume = {9},
  number = {6},
  pages = {e16547},
  issn = {2405-8440},
  doi = {10.1016/j.heliyon.2023.e16547},
  urldate = {2023-10-30},
  abstract = {SARS-CoV-2-specific antibody measurement is important for evaluating COVID-19 vaccine efficacy. We quantified and compared anti-spike (S) antibodies using different commercial immunoassays. We tested serum samples from 70 SARS-CoV-2-naive health care workers 2 weeks after vaccination with a single dose of BNT162b2, 2 and 4 weeks, and 3 months after the second dose of BNT162b2. The following quantitative assays were used: Roche Elecsys Anti-SARS-CoV-2 S (Roche-S), Abbott SARS-CoV-2 IgG II Quant [Abbott-IgG(S)], and Abbott SARS-CoV-2 IgM (Abbott-IgM). All samples tested positive for Roche-S and Abbott-IgG antibodies after the second dose, with 83.6\% Abbott-IgM positive rate. Roche-S and Abbott-IgG(S) correlated significantly in all samples (r~=~0.920, p~{$<~$}0.0001), and the Roche-S and Abbott-IgG(S) assay showed a strong correlation with each other at each time point after vaccination. Roche-S and Abbott-IgG(S) antibody titers were correlated with age; their rate of decline was age-dependent in males but not in females. Abbott-IgG(S) antibody titers decreased from 2 weeks after the second dose. Roche-S antibody titers peaked 2 weeks after the second dose in 76.2\% of the participants; the titers recovered 3 months post-vaccination after declining at week 4 in 40.7\% of the participants. The concordance between Roche-S and Abbott-IgG(S) antibody titers over time was 47.5\%. Most participants presented significantly high Roche-S and Abbott-IgG(S) antibody titers after immunization. Some measurements were inconsistent with titer changes between these assays, possibly because of differences in the immunoglobulin-specificity of the kits.},
  keywords = {Antibody,BNT-162b2 vaccine,Immunoassays,Immunological response,SARS-CoV-2},
  file = {C\:\\Users\\jchen\\Zotero\\storage\\7FTZCHMH\\Nakai et al. - 2023 - Variation in antibody titers determined by Abbott .pdf;C\:\\Users\\jchen\\Zotero\\storage\\W7TSZ2B2\\S2405844023037544.html}
}

@article{Nikiforuk2022,
  title = {Performance of {{Immunoglobulin G Serology}} on {{Finger Prick Capillary Dried Blood Spot Samples}} to {{Detect}} a {{SARS-CoV-2 Antibody Response}}},
  author = {Nikiforuk, Aidan M. and McMillan, Brynn and Bartlett, Sofia R. and M{\'a}rquez, Ana Citlali and Pidduck, Tamara and Kustra, Jesse and Goldfarb, David M. and Barakauskas, Vilte and Sinclair, Graham and Patrick, David M. and Sadarangani, Manish and Ogilvie, Gina S. and Krajden, Mel and Morshed, Muhammad and Sekirov, Inna and Jassem, Agatha N.},
  year = {2022},
  month = mar,
  journal = {Microbiology Spectrum},
  volume = {10},
  number = {2},
  pages = {e01405-21},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/spectrum.01405-21},
  urldate = {2023-11-16},
  abstract = {We investigate the diagnostic accuracy and predictive value of finger prick capillary dried blood spot (DBS) samples tested by a quantitative multiplex anti-immunoglobulin G (IgG) assay to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies after infection or vaccination. This cross-sectional study involved participants (n\,=\,6,841) from several serological surveys conducted in nonhospitalized children and adults throughout 2020 and 2021 in British Columbia (BC), Canada. Analysis used paired DBS and serum samples from a subset of participants (n\,=\,642) prior to vaccination to establish signal thresholds and calculate diagnostic accuracy by logistic regression. Discrimination of the logistic regression model was assessed by receiver operator curve (ROC) analysis in an n\,=\,2,000 bootstrap of the paired sample (n\,=\,642). The model was cross-validated in a subset of vaccinated persons (n\,=\,90). Unpaired DBS samples (n\,=\,6,723) were used to evaluate anti-IgG signal distributions. In comparison to paired serum, DBS samples from an unvaccinated population possessed a sensitivity of 79\% (95\% confidence interval [95\% CI]: 58 to 91\%) and specificity of 97\% (95\% CI: 95 to 98\%). ROC analysis found that DBS samples accurately classify SARS-CoV-2 seroconversion at an 88\% percent rate (area under the curve [AUC] = 88\% [95\% CI: 80 to 95\%]). In coronavirus disease 2019 (COVID-19) vaccine dose one or two recipients, the sensitivity of DBS testing increased to 97\% (95\% CI: 83 to 99\%) and 100\% (95\% CI: 88 to 100\%). Modeling found that DBS testing possesses a high positive predictive value (98\% [95\% CI: 97 to 98\%]) in a population with 75\% seroprevalence. We demonstrate that DBS testing should be considered to reliably detect SARS-CoV-2 seropositivity from natural infection or vaccination. IMPORTANCE Dried blood spot samples have comparable diagnostic accuracy to serum collected by venipuncture when tested by an electrochemiluminescent assay for antibodies and should be considered to reliably detect seropositivity following SARS-CoV-2 infection and/or vaccination.},
  file = {C:\Users\jchen\Zotero\storage\BX5VJF36\Nikiforuk et al. - 2022 - Performance of Immunoglobulin G Serology on Finger.pdf}
}

@article{Raina2019,
  title = {Cohort {{Profile}}: {{The Canadian Longitudinal Study}} on {{Aging}} ({{CLSA}})},
  shorttitle = {Cohort {{Profile}}},
  author = {Raina, Parminder and Wolfson, Christina and Kirkland, Susan and Griffith, Lauren E and Balion, Cynthia and Cossette, BenoÈ‹t and Dionne, Isabelle and Hofer, Scott and Hogan, David and {van den Heuvel}, E R and {Liu-Ambrose}, Teresa and Menec, Verena and Mugford, Gerald and Patterson, Christopher and Payette, H{\'e}l{\`e}ne and Richards, Brent and Shannon, Harry and Sheets, Debra and Taler, Vanessa and Thompson, Mary and Tuokko, Holly and Wister, Andrew and Wu, Changbao and Young, Lynne},
  year = {2019},
  month = dec,
  journal = {International Journal of Epidemiology},
  volume = {48},
  number = {6},
  pages = {1752-1753j},
  issn = {0300-5771},
  doi = {10.1093/ije/dyz173},
  urldate = {2023-06-27},
  file = {C:\Users\jchen\Zotero\storage\6R5EZDAY\Raina et al. - 2019 - Cohort Profile The Canadian Longitudinal Study on.pdf}
}

@article{Saeed2021,
  title = {Severe Acute Respiratory Syndrome Coronavirus 2 ({{SARS-CoV-2}}) Seroprevalence: {{Navigating}} the Absence of a Gold Standard},
  shorttitle = {Severe Acute Respiratory Syndrome Coronavirus 2 ({{SARS-CoV-2}}) Seroprevalence},
  author = {Saeed, Sahar and O'Brien, Sheila F. and Abe, Kento and Yi, Qi-Long and Rathod, Bhavisha and Wang, Jenny and {Fazel-Zarandi}, Mahya and Tuite, Ashleigh and Fisman, David and Wood, Heidi and Colwill, Karen and Gingras, Anne-Claude and Drews, Steven J.},
  year = {2021},
  month = sep,
  journal = {PLOS ONE},
  volume = {16},
  number = {9},
  pages = {e0257743},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0257743},
  urldate = {2023-11-27},
  abstract = {Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies bridge the gap left from case detection, to estimate the true burden of the COVID-19 pandemic. While multiple anti-SARS-CoV-2 immunoassays are available, no gold standard exists. Methods This serial cross-sectional study was conducted using plasma samples from 8999 healthy blood donors between April-September 2020. Each sample was tested by four assays: Abbott SARS-Cov-2 IgG assay, targeting nucleocapsid (Abbott-NP) and three in-house IgG ELISA assays (targeting spike glycoprotein, receptor binding domain, and nucleocapsid). Seroprevalence rates were compared using multiple composite reference standards and by a series of Bayesian Latent Class Models. Result We found 13 unique diagnostic phenotypes; only 32 samples (0.4\%) were positive by all assays. None of the individual assays resulted in seroprevalence increasing monotonically over time. In contrast, by using the results from all assays, the Bayesian Latent Class Model with informative priors predicted seroprevalence increased from 0.7\% (95\% credible interval (95\% CrI); 0.4, 1.0\%) in April/May to 0.7\% (95\% CrI 0.5, 1.1\%) in June/July to 0.9\% (95\% CrI 0.5, 1.3) in August/September. Assay characteristics varied over time. Overall Spike had the highest sensitivity (93.5\% (95\% CrI 88.7, 97.3\%), while the sensitivity of the Abbott-NP assay waned from 77.3\% (95\% CrI 58.7, 92.5\%) in April/May to 64.4\% (95\% CrI 45.6, 83.0) by August/September. Discussion Our results confirmed very low seroprevalence after the first wave in Canada. Given the dynamic nature of this pandemic, Bayesian Latent Class Models can be used to correct for imperfect test characteristics and waning IgG antibody signals.},
  langid = {english},
  keywords = {Antibodies,Blood donors,COVID 19,Enzyme-linked immunoassays,Glycoproteins,Nucleocapsids,SARS CoV 2,Virus testing},
  file = {C:\Users\jchen\Zotero\storage\IAI3RHTW\Saeed et al. - 2021 - Severe acute respiratory syndrome coronavirus 2 (S.pdf}
}

@article{Schaack2020a,
  title = {418. {{Comparison}} of the {{Abbott SARS-CoV-2 IgG}} and {{DiaSorin LIASON SARS-CoV-2 S1}}/{{S2 IgG Antibody Assays}}},
  author = {Schaack, Grace A and Chen, Derrick},
  year = {2020},
  month = oct,
  journal = {Open Forum Infectious Diseases},
  volume = {7},
  number = {Supplement\_1},
  pages = {S276-S277},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofaa439.612},
  urldate = {2023-10-30},
  abstract = {The Abbott Laboratories SARS-CoV-2 IgG assay and the DiaSorin LIASON SARS-CoV-2 S1/S2 IgG assay are both chemiluminescent immunoassays that qualitatively detect IgG antibodies against SARS-CoV-2 antigens. The Abbott assay detects IgG against the viral nucleocapsid (N) protein, while the DiaSorin assay uses antigen derived from the viral spike (S) protein. Here we evaluate the performance of these two assays at our institution.45 patient samples (serum or plasma) were tested for anti-SARS-CoV-2 IgG by both the Abbott and DiaSorin assays. The samples were previously characterized at a national reference laboratory using the Abbott assay or by an in-house PCR-based test for SARS-CoV-2 RNA. Samples yielding discordant results across platforms were further tested using the EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) assay at the reference laboratory.22 samples tested negative for SARS-CoV-2 by the reference lab Abbott assay, and 23 tested positive by the same reference lab test (n = 13) or by an in-house PCR-based test (n = 10). The 22 samples characterized as negative again tested negative by both the Abbott (in-house) and DiaSorin assays (100\% NPA). Among the 23 samples characterized as positive, all 23 tested positive by the Abbott assay (100\% PPA), while only 15 tested positive by the DiaSorin assay (65\% PPA). For each of the 8 discordant cases, samples were further tested by EUROIMMUN assay, which targets the S protein; 7 of the 8 samples tested negative by this assay, in agreement with the DiaSorin test results. Thus, for the discordant cases, testing for IgG against N (in-house and reference lab Abbott assays) gave positive results, while testing for IgG against S (DiaSorin and EUROIMMUN assays) mostly gave negative results.These findings highlight the importance of the differences between various SARS-CoV-2 antibody tests, and providers should be aware of the specific antigenic target(s) in each test. Selection of a specific assay may depend on the need to assess past exposure to SARS-CoV-2 (for which a nucleocapsid target may be more sensitive) or to detect neutralizing antibodies (for which a spike target may be more relevant). This also has implications for disease surveillance as reliance on anti-spike antibodies alone may underestimate infection prevalence.All Authors: No reported disclosures},
  file = {C\:\\Users\\jchen\\Zotero\\storage\\XLYUFMQS\\Schaack and Chen - 2020 - 418. Comparison of the Abbott SARS-CoV-2 IgG and D.pdf;C\:\\Users\\jchen\\Zotero\\storage\\UQ6A2J3H\\6057209.html}
}

@article{Simmonds2011,
  title = {A Comparison of Capillary and Venous Blood Sampling Methods for the Use in Haemorheology Studies},
  author = {Simmonds, Michael J. and Baskurt, Oguz K. and Meiselman, Herbert J. and {Marshall-Gradisnik}, Sonya M.},
  year = {2011},
  month = jan,
  journal = {Clinical Hemorheology and Microcirculation},
  volume = {47},
  number = {2},
  pages = {111--119},
  publisher = {{IOS Press}},
  issn = {1386-0291},
  doi = {10.3233/CH-2010-1372},
  urldate = {2023-11-09},
  abstract = {There is accumulating evidence that exercise may improve disturbed haemorheological parameters that are typically observed in various chronic diseases, thus there is a growing interest in exploring the influence of various exercise models for the imp},
  langid = {english},
  file = {C:\Users\jchen\Zotero\storage\9TC6TSA6\Simmonds et al. - 2011 - A comparison of capillary and venous blood samplin.pdf}
}

@article{Tuite2022,
  title = {Estimating {{SARS-CoV-2 Seroprevalence}} in {{Canadian Blood Donors}}, {{April}} 2020 to {{March}} 2021: {{Improving Accuracy}} with {{Multiple Assays}}},
  shorttitle = {Estimating {{SARS-CoV-2 Seroprevalence}} in {{Canadian Blood Donors}}, {{April}} 2020 to {{March}} 2021},
  author = {Tuite, Ashleigh R. and Fisman, David and Abe, Kento T. and Rathod, Bhavisha and Pasculescu, Adrian and Colwill, Karen and Gingras, Anne-Claude and Yi, Qi-Long and O'Brien, Sheila F. and Drews, Steven J.},
  year = {2022},
  month = feb,
  journal = {Microbiology Spectrum},
  volume = {10},
  number = {1},
  pages = {e02563-21},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/spectrum.02563-21},
  urldate = {2023-11-27},
  abstract = {We have previously used composite reference standards and latent class analysis (LCA) to evaluate the performance of laboratory assays in the presence of tarnished gold standards. Here, we apply these techniques to repeated, cross-sectional study of Canadian blood donors, whose sera underwent parallel testing with four separate SARS-CoV-2 antibody assays. We designed a repeated cross-sectional design with random cross-sectional sampling of all available retention samples (n\,=\,1500/month) for a 12 -month period from April 2020 until March 2021. Each sample was evaluated for SARS-CoV-2 IgG antibodies using four assays an Abbott Architect assay targeting the nucleocapsid antigen (Abbott-NP, Abbott, Chicago IL) and three in-house IgG ELISAs recognizing distinct recombinant viral antigens: full-length spike glycoprotein (Spike), spike glycoprotein receptor binding domain (RBD) and nucleocapsid (NP). We used two analytic approaches to estimate SAR-CoV-2 seroprevalence: a composite reference standard and LCA. Using LCA to estimate true seropositivity status based on the results of the four antibody tests, we estimated that seroprevalence increased from 0.8\% (95\% CI: 0.5--1.4\%) in April 2020 to 6.3\% (95\% CI: 5.1--7.6\%) in March 2021. Our study provides further support for the use of LCA in upcoming public health crises, epidemics, and pandemics when a gold standard assay may not be available or identifiable. IMPORTANCE Here, we describe an approach to estimating seroprevalence in a low prevalence setting when multiple assays are available and yet no known gold standard exists. Because serological studies identify cases through both diagnostic testing and surveillance, and otherwise silent, unrecognized infections, serological data can be used to estimate the true infection fatality ratio of a disease. However, seroprevalence studies rely on assays with imperfect sensitivity and specificity. Seroreversion (loss of antibody response) also occurs over time, and with the advent of vaccination, distinction of antibody response resulting from vaccination as opposed to antibody response due to infection has posed an additional challenge. Our approach indicates that seroprevalence on Canadian blood donors by the end of March 2021was less than 10\%. Our study supports the use of latent class analysis in upcoming public health crises, epidemics, and pandemics when a gold standard assay may not be available or identifiable.},
  file = {C:\Users\jchen\Zotero\storage\TIABRE2L\Tuite et al. - 2022 - Estimating SARS-CoV-2 Seroprevalence in Canadian B.pdf}
}

@article{Wiens2022,
  title = {Building an Integrated Serosurveillance Platform to Inform Public Health Interventions: {{Insights}} from an Experts' Meeting on Serum Biomarkers},
  shorttitle = {Building an Integrated Serosurveillance Platform to Inform Public Health Interventions},
  author = {Wiens, Kirsten E. and Jauregui, Barbara and Arnold, Benjamin F. and Banke, Kathryn and Wade, Djibril and Hayford, Kyla and Denis, Adriana Costero-Saint and Hall, Robert H. and Salje, Henrik and {Rodriguez-Barraquer}, Isabel and Azman, Andrew S. and Vernet, Guy and Leung, Daniel T. and Surveillance, on behalf of the Collaboration on Integrated Biomarkers},
  year = {2022},
  month = oct,
  journal = {PLOS Neglected Tropical Diseases},
  volume = {16},
  number = {10},
  pages = {e0010657},
  publisher = {{Public Library of Science}},
  issn = {1935-2735},
  doi = {10.1371/journal.pntd.0010657},
  urldate = {2023-11-09},
  abstract = {Author summary The use of biomarkers to measure immune responses in serum is crucial for understanding population-level exposure and susceptibility to human pathogens. Advances in sample collection, multiplex testing, and computational modeling are transforming serosurveillance into a powerful tool for public health program design and response to infectious threats. In July 2018, 70 scientists from 16 countries met to perform a landscape analysis of approaches that support an integrated serosurveillance platform, including the consideration of issues for successful implementation. Here, we summarize the group's insights and proposed roadmap for implementation, including objectives, technical requirements, ethical issues, logistical considerations, and monitoring and evaluation.},
  langid = {english},
  keywords = {Antibodies,Biomarkers,Infectious disease surveillance,Pathogens,Public and occupational health,Respiratory infections,Serology,Virus testing},
  file = {C:\Users\jchen\Zotero\storage\83TMHYYG\Wiens et al. - 2022 - Building an integrated serosurveillance platform t.pdf}
}

@article{Zava2021,
  title = {Validation of Dried Blood Spot Sample Modifications to Two Commercially Available {{COVID-19 IgG}} Antibody Immunoassays},
  author = {Zava, Theodore T and Zava, David T},
  year = {2021},
  month = jan,
  journal = {Bioanalysis},
  volume = {13},
  number = {1},
  pages = {13--28},
  publisher = {{Future Science}},
  issn = {1757-6180},
  doi = {10.4155/bio-2020-0289},
  urldate = {2023-10-05},
  abstract = {Aim: Coronavirus disease 2019 antibody testing often relies on venous blood collection, which is labor-intensive, inconvenient and expensive compared with finger-stick capillary dried blood spot (DBS) collection. The purpose of our work was to determine if two commercially available anti-severe acute respiratory syndrome coronavirus 2 enzyme-linked immunosorbent assays for IgG antibodies against spike S1 subunit and nucleocapsid proteins could be validated for use with DBS. Materials \& methods: Kit supplied reagents were used to extract DBS, and in-house DBS calibrators were included on every run. Results: Positive/negative concordance between DBS and serum was 100/99.3\% for the spike S1 subunit assay and 100/98\% for the nucleocapsid assay. Conclusion: Validation of the DBS Coronavirus disease 2019 IgG antibody assays demonstrated that serum and DBS can produce equivalent results with minimal kit modifications.},
  keywords = {antibody,COVID-19,DBS,dried blood spot,ELISA,filter paper,IgG,pandemic,SARS-CoV-2},
  file = {C:\Users\jchen\Zotero\storage\DAP3WY4V\Zava and Zava - 2021 - Validation of dried blood spot sample modification.pdf}
}
